You are here

  • Home
  • Archive
  • Volume 12, Issue 7
  • Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

 

Online download statistics by month:

Online download statistics by month: July 2024 to February 2026

AbstractFullPdf
Jul 2024431433164
Aug 2024556558198
Sep 2024209211415
Oct 2024245246241
Nov 2024335337118
Dec 2024346351113
Jan 202526726893
Feb 2025263264109
Mar 202525025299
Apr 2025300300106
May 2025287287106
Jun 202526326382
Feb 2026110
Total375337711844